Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The partnership also sets the stage for broader collaboration on rare disease treatments
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Subscribe To Our Newsletter & Stay Updated
